Efficacy of Spironolactone Compared with Doxycycline in Moderate Acne in Adult Females: Results of the Multicentre, Controlled, Randomized, Double-blind Prospective and Parallel Female Acne Spironolactone vs doxyCycline Efficacy (FASCE) Study

Archive ouverte

Dréno, Brigitte | Nguyen, Jean-Michel | Hainaut, Ewa | Machet, Laurent | Leccia, Marie-Thérèse | Beneton, Nathalie | Claudel, Jean-Paul | Célérier, Philippe | Le Moigne, Marie | Le Naour, Sarah | Vrignaud, Florence | Poinas, Alexandra | Dert, Cécile | Boisrobert, Aurélie | Flet, Laurent | Korner, Simon | Khammari, Amir

Edité par CCSD ; Society for Publication of Acta Dermato-Venereologica -

International audience. Acne in adult females is triggered mainly by hormones. Doxycycline is a reference treatment in acne. Spironolactone targets the androgen receptor of sebaceous glands and is prescribed off-label for female adult acne. This multicentre, controlled, randomized, double-blind prospective and parallel study assessed the efficacy of spironolactone compared with doxycycline in adult female acne. A total of 133 women with moderate acne were randomized to receive treatment with: (i) doxycycline and benzoyl peroxide for 3 months followed by a 3-month treatment with its placebo and benzoyl peroxide, or (ii) spironolactone and benzoyl peroxide for 6 months. Successfully treated patients continued with benzoyl peroxide or spironolactone alone for a further 6 months. Primary endpoints were treatment success at month 4 and month 6 with the AFAST score. At all visits, the ECLA score, lesion counts, local and systemic safety and quality of life were assessed. Spironolactone performed better at month 4 and showed a statistically significant better treatment success after 6 months than doxycycline (p = 0.007). Spironolactone was 1.37-times and 2.87-times more successful compared with doxycycline at respective time-points. AFAST and ECLA scores, as well as lesion counts always improved more with spironolactone. Patients’ quality of life was better with spironolactone at month 4 and month 6. Spironolactone was very well tolerated. This is the first study to show that, in female adults with moderate acne, treatment with spironolactone is significantly more successful than doxycycline and very well tolerated.

Suggestions

Du même auteur

FASCE, the benefit of spironolactone for treating acne in women: study protocol for a randomized double-blind trial

Archive ouverte | Poinas, Alexandra | CCSD

International audience. Background: Acne vulgaris has increased in women over the past 10 years; it currently affects 20-30% of women. The physiopathology of adult female acne is distinguished from that of teenagers...

Adult acne in women is not associated with a specific type of Cutibacterium acnes

Archive ouverte | Saint-Jean, Mélanie | CCSD

International audience. No abstract available

Insulin Growth Factor-1 Status in Hidradenitis Suppurativa: A French Institutional Pilot Study

Archive ouverte | Rousseau, Perrine | CCSD

International audience. Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease of the follicles in the apocrine glands and is associated with a deficiency in the innate immunity of the skin...

Chargement des enrichissements...